<DOC>
	<DOCNO>NCT01218542</DOCNO>
	<brief_summary>Brain metastasis common adult intracranial tumor , occur approximately 10 % 30 % adult cancer patient , represent important cause morbidity mortality . The widely use treatment patient multiple brain metastasis whole brain radiation therapy ( WBRT ) . The use WBRT resection stereotactic radiosurgery ( SRS ) proven effective term improve local control brain metastasis . RapidArc ( RA ) ( Varian Medical Systems , Palo Alto , CA ) new method deliver radiation use `` arcs '' deliver highly conformal intensity modulate three dimensional dose distribution . The purpose investigation evaluate alternative strategy give WBRT highly focal boost gross visible lesion patient brain metastasis . Given limitation SRS boost technique , purpose investigation evaluate alternative strategy give WBRT highly focal boost gross visible lesion patient brain metastasis . In study , plan assess tolerability use volumetric modulate arc therapy ( RapidArc ) patient brain metastasis simultaneously treat entire brain concomitant focal boost grossly identify lesion MRI scan try improve local control reduce neurocognitive toxicity . This previous version study phase I dose escalation trial give 25 Gy 10 fraction whole brain simultaneous infield boost ( SIB ) total 45 Gy 10 fraction gross brain metastatic disease . Prior , patient enrol onto one two cohort whole brain dose 30 Gy 10 fraction SIB total 45 Gy 10 fraction gross brain metastatic disease whole brain dose 37.5 Gy 15 fraction SIB total 52.5 Gy 15 fraction gross brain metastatic disease . A total 12 patient previously enrol trial . No patient experience dose limiting toxicity ( grade 3 ) least possibly due study therapy . Also , patient experience local brain failure/progression site treat metastatic brain disease . Based , longer feel dose escalation gross brain disease warrant would proceed single arm pilot study treat patient 25 Gy 10 fraction whole brain simultaneous infield boost ( SIB ) total 45 Gy 10 fraction gross brain metastatic disease .</brief_summary>
	<brief_title>Whole Brain Radiation Therapy With Boost Metastatic Tumor Volume Using RapidArc</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Pathologic proven diagnosis solid tumor malignancy . Age ≥ 18 . KPS ≥ 70 . Mini Mental Status Exam ( MMSE ) ≥ 18 prior study entry . RPA class I ( KPS ≥ 70 , primary cancer control , age &lt; 65 , metastasis brain ) class II ( lack one class I criteria ) . One ten brain metastatic lesion . Previous whole brain radiation therapy . Previous radiosurgery currently progressive gross metastatic disease . Previous radiosurgery intracranial site within prior 6 week . Recursive partitioning analysis ( RPA ) class III ( KPS &lt; 70 ) . Radiosensitive ( eg . small cell lung carcinoma , germ cell tumor , leukemia , lymphoma ) unknown tumor histology . Concurrent chemotherapy ( chemotherapy start 14 day start radiation ) . Evidence leptomeningeal disease MRI and/or cerebrospinal fluid ( CSF ) cytology . Current pregnancy . No metastasis brain stem , midbrain , pons , medulla within 7 mm optic apparatus ( optic nerve chiasm ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Secondary brain malignancy</keyword>
	<keyword>RapidArc</keyword>
	<keyword>Volumetric modulate arc therapy</keyword>
</DOC>